



EISAI CONCLUDES JAPAN LICENSE AGREEMENT FOR NEW ARICEPT® TRANSDERMAL FORMULATION

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has concluded an exclusive license agreement with Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, President & CEO: Shosaku Murayama, “Teikoku Seiyaku”) concerning the research, development and marketing of a new transdermal formulation of Aricept® (an adhesive skin patch containing either donepezil hydrochloride or donepezil) for the treatment of Alzheimer’s disease in Japan.

The agreement was concluded following Eisai’s decision to exercise its option to enter an exclusive Japan license agreement to research, develop and market the Aricept® transdermal formulation, for which Eisai will supply the active pharmaceutical ingredients for clinical and non-clinical use and Teikoku Seiyaku will develop. By exercising this option, Eisai will now be able to pursue the research, development and later the marketing of the new formulation in Japan.

The Aricept® transdermal formulation is characterized by the fact that it is unaffected by diet, gastrointestinal absorption or met